Active, not recruitingPhase 3NCT06508658
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Studying Diffuse large B-cell lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Genmab
- Principal Investigator
- ABBVIE INC.AbbVie
- Intervention
- Epcoritamab(drug)
- Enrollment
- 379 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2028
Study locations (30)
- City of Hope National Medical Center /ID# 273338, Duarte, California, United States
- Valkyrie Clinical Trials /ID# 269935, Los Angeles, California, United States
- Desert Regional Medical Center /ID# 272437, Palm Springs, California, United States
- Lutheran Medical Center- Cancer Centers of Colorado /ID# 265823, Golden, Colorado, United States
- City Of Hope - Atlanta. /ID# 273092, Newnan, Georgia, United States
- Rush University Medical Center /ID# 242103, Chicago, Illinois, United States
- City Of Hope - Chicago /ID# 274430, Zion, Illinois, United States
- Northwest Cancer Center - Dyer Clinic /ID# 269787, Dyer, Indiana, United States
- Cancer Center of Kansas - Wichita /ID# 270117, Wichita, Kansas, United States
- University of Kentucky Chandler Medical Center. /ID# 242087, Lexington, Kentucky, United States
- University of Maryland, Baltimore /ID# 242216, Baltimore, Maryland, United States
- Henry Ford Hospital /ID# 266446, Detroit, Michigan, United States
- Gulfport Memorial Hospital /ID# 268104, Gulfport, Mississippi, United States
- New York Medical College /ID# 265799, Valhalla, New York, United States
- East Carolina University - Brody School of Medicine /ID# 242227, Greenville, North Carolina, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
AbbVie
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06508658 on ClinicalTrials.govOther trials for Diffuse large B-cell lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07365306Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaCity of Hope Medical Center
- RECRUITINGPHASE3NCT07493109Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOPOu Bai, MD/PHD
- RECRUITINGPHASE2NCT07493148Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCLOu Bai, MD/PHD
- RECRUITINGPHASE3NCT07409428A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCLHutchmed
- RECRUITINGPHASE2NCT07397832CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCLTianjin Medical University Cancer Institute and Hospital
- RECRUITINGPHASE3NCT07188558A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell TherapyLyell Immunopharma, Inc.
- RECRUITINGPHASE2NCT07499271Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 MutationThe First Affiliated Hospital of Soochow University
- RECRUITINGPHASE2NCT07189065A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell LymphomaGuangzhou Lupeng Pharmaceutical Company LTD.